

Prevalence of Anxiety and Depressive Disorders in a Sample of Moscow Residents: Comparison of the GAD-7 and HADS Results with a Clinical Assessment

Оценка распространенности тревожно-депрессивных расстройств на выборке жителей Москвы: сравнение данных самоопросников GAD-7 и HADS с клинической оценкой врача-психиатра

doi: 10.17816/CP15487

Original research

Valeriya Savenkova¹, Yana Zorkina^{1,2},
Alexandra Ochneva^{1,2}, Angelina Zeltzer¹,
Darya Ryabinina¹, Anna Tsurina^{1,3},
Elizaveta Golubeva^{1,4}, Anna Goncharova⁵,
Irina Alekseenko^{5,6,7}, George Kostyuk¹,
Anna Morozova^{1,2}

¹ Mental-health clinic No. 1 named after N.A. Alexeev, Moscow, Russia

² V. Serbsky National Medical Research Centre of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, Moscow, Russia

³ Pirogov Russian National Research Medical University, Moscow, Russia

⁴ I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

⁵ Moscow center for healthcare innovations, Moscow, Russia

⁶ Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

⁷ Kurchatov Institute, Moscow, Russia

Валерия Савенкова¹, Яна Зоркина^{1,2},
Александра Очнева^{1,2}, Ангелина Зельцер¹,
Дарья Рябинина¹, Анна Цурина^{1,3},
Елизавета Голубева^{1,4}, Анна Гончарова⁵,
Ирина Алексеенко^{5,6,7}, Георгий Костюк¹,
Анна Морозова^{1,2}

¹ ГБУЗ «Психиатрическая клиническая больница № 1 им. Н.А. Алексеева Департамента здравоохранения города Москвы», Москва, Россия

² ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России, Москва, Россия

³ ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия

⁴ ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет), Москва, Россия

⁵ Московский центр инновационных технологий в здравоохранении, Москва, Россия

⁶ Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова, Москва, Россия

⁷ НИЦ «Курчатовский институт», Москва, Россия

ABSTRACT

BACKGROUND: Anxiety and depressive disorders are the most common mental disorders. Detecting a disorder at an early stage can prevent the development of severe disorders and preserve the patient's functioning ability. Simple and reliable screening tools based on self-completion of questionnaires can be used for this purpose. However, it is not always the case that the scores of the self-questionnaire align with those of the clinician.

AIM: To estimate the prevalence of anxiety-depressive disorders using the GAD-7 and HADS self-report questionnaires compared to psychiatrist assessment.

METHODS: The study included individuals aged 18 to 65 years, living in Moscow, Russia, without psychiatric disorders, who participated in an online study using the HADS (Hospital Anxiety and Depression Scale, HADS-A and HADS-D) and GAD-7 (Generalized Anxiety Disorder 7-item scale). Anxiety disorder was diagnosed when the total score was ≥ 10 on the GAD-7 and/or ≥ 10 on the HADS-A scale, and depression was defined when the total score was ≥ 9 on the HADS-D scale. Then, 82 randomly selected participants attended an anonymous consultation with a psychiatrist.

RESULTS: The study included 1,097 individuals (72% female), median age 29 (23; 37) years. As a result of testing, anxiety disorder was found in 168 (15%); depressive disorder — in 152 (14%) respondents. At medical verification, anxiety was diagnosed in 18 (22%); depression — in 19 (23%) people. The sensitivity of the HADS-D subscale for physician-diagnosed cases of depression was 61%, and specificity was 73%. The sensitivity of the HADS-A and GTR-7 subscale in identifying cases of anxiety disorder was 58%, specificity 59%. Sixteen percent were first diagnosed with a personality disorder or schizotypal disorder.

CONCLUSION: The level of anxiety and depression in our sample of the population of Moscow, Russia, was higher than the global level. Self-assessment based on the questionnaire seems to not fully reflect the real state of a patient, as evidenced by the differences with the psychiatrist's assessment.

АННОТАЦИЯ

ВВЕДЕНИЕ: Тревожные и депрессивные расстройства — наиболее распространенные психиатрические заболевания. Выявление патологии на ранней стадии может предотвратить развитие серьезных нарушений и сохранить работоспособность пациента. В этом могут помочь простые и надежные скрининговые инструменты, основанные на самостоятельном заполнении опросников. Однако не всегда оценки самоопросника совпадают с клинической оценкой специалиста.

ЦЕЛЬ: Оценить распространенность тревожно-депрессивных расстройств с помощью госпитальной шкалы тревоги и депрессии (Hospital Anxiety and Depression Scale, HADS) и самоопросника генерализованного тревожного расстройства (Generalized Anxiety Disorder-7, GAD-7) и сравнить результат с клиническим заключением психиатра.

МЕТОДЫ: В исследование включили лиц без психических расстройств от 18 до 65 лет, проживавших в г. Москве, которые приняли участие в онлайн-опросе с применением шкал HADS (HADS-A и HADS-D) и GAD-7. Тревожное расстройство определяли при суммарной оценке ≥ 10 баллов по GAD-7 и/или ≥ 10 баллов по шкале HADS-A, депрессию — при ≥ 9 баллов по шкале HADS-D. Затем 82 случайно отобранных участника прошли анонимную консультацию психиатра.

РЕЗУЛЬТАТЫ: В исследование включили 1097 человек (72% женщины), средний возраст 29 (23; 37) лет. В результате тестирования тревожное расстройство обнаружено у 168 (15%), депрессивное расстройство — у 152 (14%) опрошенных. По результатам врачебной диагностики тревога диагностирована у 18 (22%), депрессия — у 19 (23%) человек. Чувствительность подшкалы HADS-D в отношении случаев депрессии, диагностированных врачами, составила 61%, специфичность — 73%. Чувствительность подшкалы HADS-A и GAD-7 при выявлении случаев тревожного расстройства составила 58%, специфичность 59%. У 16% впервые диагностировали расстройства личности или шизотипическое расстройство.

ЗАКЛЮЧЕНИЕ: Уровень тревоги и депрессии в данной выборке из популяции г. Москва оказался повышен. Самооценка по опроснику не в полной мере отражает реальное состояние человека, о чем свидетельствуют несоответствия с оценкой психиатра.

Keywords: *depression; anxiety; urban population; GAD-7; HADS*

Ключевые слова: *депрессия; тревога; городская популяция; GAD-7; HADS*

INTRODUCTION

Today, anxiety and depressive disorders are becoming increasingly relevant, particularly in urban areas. These conditions are largely the result of the ongoing social, economic, and other challenges of our time [1]. It is estimated that over 300 million people worldwide (4.05% of the global population) suffer from anxiety [2], while around 280 million (3.8% of the population) experience depressive disorders.¹ According to the Institute for Health Metrics and Evaluation, in Russia, approximately 5,453,800 people (about 3.8%) are affected by depressive disorders, and 4,999,400 people (about 3.5%) suffer from anxiety disorders. These mental health conditions are among the most widespread in the general population.²

The World Health Organization (WHO) predicts that the prevalence of these disorders will rise significantly, with depressive disorders projected to become one of the most common types of disorders by 2030.³ The highest rates of anxiety and depressive disorders are borne by adolescents [3] and young adults — an active and working population. Recent data from 2022–2023 likewise show an increase in the prevalence of these disorders in Russia.⁴ In the ESSE-RF study, clinical depression on the Hospital Anxiety and Depression Scale (HADS) ≥ 11 points was observed in 4.5% of the study cohort (men — 3.4% and women — 5.4%); and anxiety, in 6.8% (men — 4.0% and women — 5.4%) [4].

Chronic anxiety and depressive disorders can indirectly contribute to the development of various somatic conditions, such as gastrointestinal disorders, allergic reactions, respiratory issues, cardiovascular diseases, frequent headaches, migraines, etc. Early detection of these mental health disorders can prevent the onset of more serious complications and help maintain a patient's overall ability to function [5]. Additionally, whenever a patient voices somatic complaints, it is important to rule out underlying anxiety or depression [6].

Therefore, simple and reliable screening tools for these conditions are essential. Screening can be effectively conducted using psychometric self-assessment scales [7], which provide a quick and easy method of preliminary diagnosis.

Among the most commonly used self-assessment scales are the HADS [8] and the Generalized Anxiety Disorder 7-item scales (GAD-7) [9]. These tools have been validated for identifying anxiety and depressive disorders in patients with various conditions, including cancer [10], heart disease [11, 12], neuropsychiatric disorders [13], and irritable bowel syndrome [14]. While the GAD-7 scale has not been officially validated in Russia, a Russian-language version has been adapted [15]. In 2023, the validation results of the Russian-language version of the HADS scale were published [16].

Based on studies involving different cohorts, the prevalence of anxiety, as measured on the HADS-A scale, was found to be 26% among cancer patients [17], 12% in patients with coronary heart diseases [18], 16% in those with cardiovascular diseases or diabetes [19], 14% in patients with irritable bowel syndrome, and 11% in those with chronic thromboembolic pulmonary hypertension, according to the GAD-7 scale [20]. The prevalence of depression according to the HADS-D scale was 28% in the cancer cohort [17], 20% in patients with irritable bowel syndrome [20], and 28% in patients with cardiovascular diseases or diabetes [19]. The authors observed comparable levels of anxiety in individuals with coronary heart diseases when compared to a European sample assessed using the same protocol, while they noted a higher incidence of depression in the Russian population [18]. In a previous study, we had evaluated anxiety levels among healthcare workers, revealing an increase from 16.09% in 2020 to 39.08% in 2022, alongside a rise in depression from 8.05% to 13.79%. This increase in anxiety severity contrasts with findings from earlier longitudinal studies [21].

However, the previous study had a limitation in that anxiety and depression were measured using self-reported scales (HADS), which may be prone to bias or inaccuracies due to the subjective nature of the responses. Self-assessments can also be misleading since anxiety symptoms may resemble those of somatic diseases, potentially leading to an underestimation of anxiety levels. Additionally, these symptoms can overlap with those of other mental health conditions [22]. To address potential inaccuracies stemming from this limitation, we added an additional

¹ World Health Organization (WHO). Depressive disorder (depression). Available from: <https://www.who.int/news-room/fact-sheets/detail/depression>

² About 4 million Russians suffer from mental disorders. In Russian. Available from: <https://www.interfax.ru/russia/945840>

³ Global status report on physical activity 2022. Available from: <https://iris.who.int/bitstream/handle/10665/363607/9789240059153-eng.pdf?sequence=1>

⁴ Quarterly forecast of GDP. In Russian. Available from: <https://ecfor.ru/publication/kvartalnyj-prognoz-ekonomiki-vypusk-55>

anxiety scale, the GAD-7, and evaluated the prevalence of anxiety and depressive disorders in a random sample of patients who had undergone psychiatric consultations.

Therefore, the aim of this study was to assess the prevalence of anxiety and depressive states using self-reported questionnaires in a sample of Moscow residents, followed by a comparison of these self-assessments with a psychiatrist's diagnosis.

METHODS

Study design

We conducted a cross-sectional study to assess the prevalence of anxiety and depression using screening scales, followed by clinical (physician) validation of the respondents' mental states.

Setting

The study involved 1,097 male and female participants aged 18 to 65, recruited from the Moscow population between June 2022 and September 2023.

Participants

Participants were volunteers who had responded to an invitation on social media to participate in an examination for mental disorders. Individuals with a previously diagnosed mental disorder or severe somatic diseases were excluded. The announcement provided information about the study's goals and objectives, study site, and eligibility criteria. Participants received the testing materials electronically via the Google Forms online tool (Google LLC, USA). They were asked to provide their sex, age, education level (none, primary, incomplete secondary, complete secondary, higher, academic, or degree postgraduate), place of residence, and respond to questions from the GAD-7 and HADS scales. Each participant could submit their information only once during a single session, after which they could not revisit the study results. However, participants were allowed to revise their answers while filling out the electronic form; leaving any questionnaire items blank was not permitted.

Next, 100 individuals who responded to the online questionnaire were randomly selected using the Lotto function in Excel VBA for this study. They were contacted by phone and invited to participate in a free, anonymous in-person consultation with a psychiatrist. Potential participants were informed that the consultation aimed to verify the

results of the psychometric testing conducted for research purposes. If they agreed to participate, they were given the option to select a convenient date from the available slots for a visit.

At the time of the consultation, physicians, like the study participants, were unaware of the psychometric testing results. Based on the consultation outcomes, doctors diagnosed any mental disorders present in the subjects according to ICD-10 criteria.⁵

Anxiety and depression assessment scales

In this study focused on developing a method for assessing the risk of mental disorders, psychometric testing was performed using the GAD-7 and HADS scales, both adapted into Russian. The GAD-7 scale (sensitivity 89%, specificity 82% [23]) consists of seven items, each with four response options ranked from 0 to 3 points based on the severity of anxiety symptoms [24]. The HADS scale includes two subscales: anxiety (HADS-A, specificity 94.0%, sensitivity 73.8%) and depression (HADS-D, sensitivity 72.9%, specificity 92.5%) [25]. Each subscale consists of seven items with four answer options that reflect the severity of symptoms, ranging from 0 (absence) to 3 (maximum severity) [26]. Anxiety was identified with a total score of ≥ 10 points on the GAD-7 [23] scale and/or ≥ 10 points on the HADS-A scale, while depression was indicated by a score of ≥ 9 points on the HADS-D scale [27].

Statistical analysis

The data were analyzed using the IBM SPSS Statistics software, version 26.0 (IBM, USA). Quantitative parameters were described by reporting the median along with the 25th and 75th percentiles. Anxiety and depression scores in independent groups were compared using the Kruskal-Wallis test (H-test) for three or more groups and the Mann-Whitney test (U-test) for two groups. The Pearson's chi-squared test was used to compare frequencies in independent groups. To evaluate the internal consistency of the HADS and GAD-7 scales, Cronbach's alpha coefficient was calculated (where a value of 1 indicates perfect consistency, >0.9 indicates very good consistency, >0.8 indicates good consistency, >0.7 indicates acceptable consistency, >0.6 indicates questionable consistency, >0.5 indicates poor consistency, and <0.5 indicates insufficient consistency). Differences were considered statistically significant at $p < 0.05$.

⁵ Mental and behavioral disorders related to substance use (F10-F19). In Russian. Available from: <http://mkb-10.com/index.php?pid=4048>

Ethical approval

Written informed consent was obtained from each potential participant for the use of their data for research purposes. After the consultation with a psychiatrist, all participants received the results of the psychometric assessments. The results from the psychiatrist's consultation were kept confidential and were not disclosed to the participants. The study protocol was approved by the local ethics committee of Mental-health clinic No.1 named after N.A. Alexeev, Moscow, Russia (protocol No. 1 dated January 25, 2022).

RESULTS

Sample characteristics

The database used in this study to develop a method for assessing the risk of developing a mental disorder included information from 1,097 participants, with 794 (72%) being women. The median age of the respondents was 29 years (interquartile range: 23 to 37 years). At the time of the study, 841 (77%) individuals had higher education, which included 69 participants with an academic degree, 153 (14%) with complete secondary education, and 12 (1%) with incomplete secondary education, and 91 (8%) participants did not provide information regarding their education. The median anxiety score on the GAD-7 scale was 4 points (2; 7), while the median score on the HADS-A anxiety scale was 6 points (3; 9), and on the HADS-D depression scale, it was 4 points (2; 7). Anxiety disorder was identified in 163 (14.86%) participants according to the GAD-7 scale (≥ 10 points) and in 164 (14.9%) according to the HADS-A scale (≥ 10 points). At least one of these scales indicated anxiety in 168 (15.3%) participants. Depression, as measured by the HADS-D scale (≥ 9 points), was found in 152 (13.86%) respondents.

Clinical assessment of anxiety and depression

A random selection of 82 individuals underwent an anonymous consultation with a psychiatrist. The individuals who were not part of this random sample but had also consulted a psychiatrist were comparable to the rest of the study participants in terms of age, sex, and education level (see Table 1).

Based on the psychiatrists' evaluations, among the 82 participants who had undergone consultation, 32 (39%) were deemed mentally healthy. Affective disorders characterized by a predominant depressive syndrome (referred to as "depressive disorders") were identified in 19 participants (23%). Neurotic disorders with a predominance

Table 1. Characteristics of random sample participants

Parameters	Group not included in the random sample (n=1,015)	Random sample (n=82)	U	p-value
Age, years	29 (23; 37)	27 (22; 31)	30430	0.07
Sex (female), abs. (%)	730 (72%)	64 (78%)	1.24	0.27
Education (higher), abs. (%)	778 (77%)	63 (77%)	3.16	0.08
Academic degree, abs. (%)	62 (6%)	7 (8%)	0.64	0.43
Complete secondary education, abs. (%)	141 (14%)	12 (15%)	0.03	0.86

of anxiety symptoms ("anxiety disorders") were found in 18 participants (22%), while other mental disorders were diagnosed in 13 participants (16%) (Figure 1).

The proportion of individuals displaying depressive symptoms was consistent between the test results and the psychiatrist's evaluation ($\chi^2=3.02$; $p=0.083$). Among the 18 patients diagnosed with depression by the psychiatrist, 11 showed corresponding results on the psychometric test, yielding a sensitivity index of 61%. Of the 64 patients who were not diagnosed with depression by the psychiatrist, only 17 produced positive test results (a specificity of 73%). There was a discrepancy between the test results and the psychiatrist's assessment for 24 individuals (29%) (Table 2). The proportion of individuals exhibiting anxiety symptoms differed significantly from the psychiatrist's evaluation ($\chi^2=8.8$; $p=0.004$), with a sensitivity of 58% and a specificity of 59%. There was a discrepancy between the test results and the psychiatrist's assessment for 34 individuals (41%) (Table 3).

The assessment of internal consistency showed good consistency of the scales, except for the assessment of anxiety in the group of people with other mental disorders (Table 4).

Then, the anxiety and depression scores on the scales in the groups of patients with different clinical diagnoses were compared. No such differences were found for the GAD-7 and HADS-A scales. Statistically significant differences between the groups when comparing them were found for the depression score on the HADS-D scale (Table 5).

DISCUSSION

In a study of a random sample of 1,097 people living in Moscow who responded to an invitation on social media




Figure 1. Diagnoses in the sample after clinical assessment.

Source: Savenkova et al., 2024

to participate in a scientific study of mental health, the proportion of people with an anxiety disorder was 14.9%, and this rate was similar for both scales under study (GAD-7 and HADS-A). The proportion of participants showing signs of depression, based on the HADS-D self-assessment, was 13.86%. These rates exceed the global averages, as demonstrated in previous studies conducted in Russia [7]. In comparison, during the COVID-19 pandemic, similar research found that anxiety and depression rates in a comparable sample were 14% and 8%, respectively [28]; thus, the prevalence of anxiety disorders remained steady while the proportion of depressive disorders increased. When comparing the current findings with previous studies conducted on healthcare professionals, the prevalence of depressive disorders was nearly identical (13.79% vs 13.86%). However, anxiety disorders were significantly lower in the general population (14.86%) compared to that in healthcare professionals (39.08%).

Both the GAD-7 and HADS scales, used to assess anxiety and depressive states, are brief, easy-to-complete self-questionnaires. Although the GAD-7 and HADS scales were developed to identify anxiety and depressive disorders in patients with mental or somatic disorder, there are a significant number of publications on their use in

Table 2. Comparison of psychometric testing results and clinical assessment of depressive disorder

Psychometric testing	Clinical (physician) assessment		Total
	Depression (-)	Depression (+)	
Depression (-)	47 (57%)	7 (9%)	54 (66%)
Depression (+)	17 (21%)	11 (13%)	28 (34%)
Total	64 (78%)	18 (22%)	82 (100%)

Note: (-) — absence of depression, (+) — presence of depression; (-)/(+) — for the test results, the presence of a depressive disorder was established with a total score of ≥ 9 points on the HADS-D scale.

Table 3. Comparison of psychometric testing results and the clinical assessment of anxiety disorder

Psychometric testing	Clinical (physician) assessment		Total
	Anxiety (-)	Anxiety (+)	
Anxiety (-)	37 (45%)	8 (10%)	45 (55%)
Anxiety (+)	26 (32%)	11 (13%)	37 (45%)
Total	63 (77%)	19 (23%)	82 (100%)

Note: (-) — absence of anxiety disorder, (+) — presence of anxiety disorder; (-)/(+) — for the test results, the presence of anxiety disorder was established with a total score of ≥ 10 points on the GAD-7 scale and/or ≥ 10 points on the HADS-A scale.

Table 4. Internal consistency (Cronbach's alpha) of the scales in the groups with different medical assessments of mental health

Mental health*	Scales		
	GAD-7	HADS-A	HADS-D
Mentally healthy	0.916	0.850	0.835
Anxiety disorders	0.882	0.733	0.873
Depressive disorders	0.819	0.911	0.868
Other mental disorders	0.676	0.683	0.967

Note: *Based on the results of the clinical assessment. GAD-7 — Generalized Anxiety Disorder 7-item scale; HADS — Hospital Anxiety and Depression Scale.

Table 5. Comparison of anxiety and depression scores on self-administered questionnaires in the groups with different clinical assessments of mental health

Scales	Mental health assessment by a specialist				H	p-value
	Mentally healthy (n=32)	Anxiety disorders (n=18)	Depressive disorders (n=19)	Other mental disorders (n=13)		
GAD-7 Me [Q1;Q3]	4.5 [3.0; 8.25]	9.0 [4.0; 13.5]	12.5 [6.25; 13.0]	5.0 [2.0; 11.0]	7.60	0.06
HADS-A Me [Q1;Q3]	7.0 [4.75; 9.25]	10.0 [5.0; 12.0]	12.50 [8.5; 15.5]	6.0 [4.0; 12.0]	7.57	0.06
HADS-D Me [Q1;Q3]	4.0 [2.0; 8.0]	6.0 [2.5; 10.5]	11.0 [5.25; 13.0]	6.0 [4.0; 8.0]	8.00	0.05

Note: GAD-7 — Generalized Anxiety Disorder 7-item scale; HADS — Hospital Anxiety and Depression Scale.

the general population. Table S1 in the Supplementary summarizes findings from some of these studies.

Variations in the estimated prevalence of anxiety and depressive disorders across studies can often be attributed to differences in the cutoff values used. In 2023, the Russian-language version of the HADS scale was validated for the Russian population, establishing cutoff values for detecting clinically significant forms of these disorders [16], which we applied in our study.

The participants in our study were predominantly young, with a median age of 29 years. While most research indicates that the risk of anxiety and depressive disorders tends to increase with age [29], recent evidence suggests that these disorders are increasingly affecting younger populations [30, 31].

The use of screening scales can be challenging, because results may be overestimated due to factors such as hypochondriasis, personality traits, and the subjective interpretation of questions by respondents. Sato and Kawahara (2011) found that memory tends to be selective for negative emotional states like anxiety, depression, and helplessness. The authors observed that individuals often overemphasize the significance of past negative

experiences, which was evident in the comparison of retrospective assessments with daily ones [32]. These findings are partly supported by results from Howren and Suls, who showed that individuals in an anxious mood reported more concurrent symptoms, while those in a depressed mood recalled more past symptoms [33]. Taple et al. (2019) also discovered that short anxiety and depression questionnaires, such as PROMIS, may be difficult for individuals with low health literacy. People with limited health literacy may respond differently to anxiety and depression questions compared to those with higher health literacy [34]. In 2023, a study with 30 adolescents (aged 15 to 17) who completed the GAD-7 scale every three weeks over a period of year found that individuals with identical GAD-7 scores experienced different dynamics of symptoms [35]. This suggests that symptom patterns are variable and dynamic, and that to gain a full understanding of a patient's clinical presentation, it is important to consider both the progression of symptoms over time and consult specialists to verify the diagnoses.

In our study, 82 participants from the total sample underwent an anonymous psychiatric consultation, which allowed us to divide them into four groups: 39% had

no mental disorders, 23% had affective disorders with predominant depressive symptoms, 22% had neurotic disorders with predominant anxiety symptoms, and 16% had other mental disorders. Notably, the proportion of anxiety disorders diagnosed by psychiatrists was higher than what was indicated by the self-assessment questionnaires.

It is also important to highlight that 13 participants (16%) received psychiatric diagnoses for the first time, falling into the categories of schizophrenia spectrum disorders and personality disorders. In the general population, approximately 8% have personality disorders [36], and around 1% have schizophrenia spectrum disorders [37]. Several factors could explain why such a high percentage of individuals with these diagnoses was identified in our study, especially since the participants had initially denied having any previously diagnosed mental disorders. Stigma surrounding mental health may cause people to feel ashamed or fearful of consulting a psychiatrist [38]. More broadly, lack of information, fear of judgment, and limited access to care are common reasons why people avoid seeking mental health services. However, distress from undiagnosed mental conditions may have motivated these individuals to engage in online testing and subsequently attend an in-person psychiatric consultation in our study.

The evaluation of the internal consistency of the GAD-7 and HADS questionnaire items showed that the respondents did not provide random answers. The lowest level of consistency, which indicated sufficient but not strong reliability, was observed in the anxiety scales (GAD-7 and HADS-A) for individuals diagnosed with personality disorders and schizophrenia spectrum disorders.

However, no significant differences in internal consistency for anxiety and depression assessments across the clinical groups identified by psychiatrists were found. This suggests that the participants provided thoughtful responses, reflecting their actual conditions rather than responding haphazardly. When comparing scale scores, there were significant differences in depression scores for individuals with a clinical diagnosis of depressive disorder, but no significant differences in anxiety scores across the clinical groups. Anxious affect may be a clinical symptom of depressive disorders [39]. When filling out self-assessment questionnaires, patients often report a feeling of anxiety, while depressive symptoms may take a backseat, either due to a lack of subjective complaints or because the clinical features of depression are not fully captured by the

screening questions. The clinical differentiation of anxiety and depressive disorders is a challenging task. Anxiety may be seen by clinicians as a feature of depression rather than a standalone disorder. In addition, the two conditions may also coexist as comorbidities [40]. The diagnosis may depend on the psychiatrist's experience and training, influencing whether they interpret the patient's symptoms as an independent anxiety disorder or as depression with an anxious affect [41]. Additionally, the use of ICD-10 criteria is known to be associated with a lower reliability in diagnosing anxiety disorders [42].

A limitation of this study is the biased sample. The study involved residents of a large metropolitan area, with a sample characterized by a high proportion of women, individuals with higher education, and those with mental disorders, as identified by the psychiatrists who consulted the participants. People who are interested in their mental health and take part in such studies are more likely to either have or suspect they have a mental disorder. However, it is very difficult to overcome this limitation and many studies relying on volunteers for participation face similar biases. Furthermore, in different regions of Russia, various economic, socio-demographic, and environmental factors may take precedence in influencing mental health, which may result in different findings [43, 44]. In large cities like Moscow, however, anxiety and depressive disorders are particularly prevalent. The limitations of online testing, as noted in previous research, also apply to this study [28].

CONCLUSION

The anxiety and depression levels among a random sample of Moscow residents who participated in an online mental health study were found to exceed global averages, reaching approximately 14%.

The proportion of individuals with depressive symptoms, as measured by scales, was similar to the clinical evaluations conducted by psychiatrists, while the assessments of anxiety symptoms were overestimated based on the test results.

Early diagnosis of anxiety and depressive disorders is a critical issue, and while self-administered screening scales can help address the problem, their reliability remains limited.

Future research should concentrate on the development of integrated approaches that combine the ease and accessibility of psychometric tools with the precision of clinical interviews.

Article history

Submitted: 08.12.2023

Accepted: 27.09.2024

Published Online: 09.12.2024

Authors' contribution: All the authors made a significant contribution to the article, checked and approved its final version prior to publication.

Funding: The study was supported by Grant No. 2707-2/22 from the Moscow Center for Innovative Technologies in Healthcare.

Conflict of interest: The authors declare no conflicts of interest.

Supplementary data

Supplementary material to this article can be found in the online version:

Table S1: <https://doi.org/10.17816/CP15487-145377>

For citation:

Savenkova VI, Zorkina YaA, Ochneva AG, Zeltzer AI, Ryabinina DA, Tsurina AM, Golubeva EA, Goncharova AS, Alekseenko IV, Kostyuk GP, Morozova AY. Prevalence of anxiety and depressive disorders in a sample of Moscow residents: comparison of the GAD-7 and HADS results with a clinical assessment. *Consortium Psychiatricum*. 2024;5(4):CP15487. doi: 10.17816/CP15487

Information about the authors

***Valeriya Igorevna Savenkova**, Junior researcher, Scientific and Clinical Research Center for Neuropsychiatry, Mental-health clinic No. 1 named after N.A. Alexeev; e-Library SPIN-code: 3172-2782,

Scopus Author ID: 57224724283,

ORCID: <https://orcid.org/0000-0002-8381-5445>

E-mail: i@savva9806.ru

Yana Alexandrovna Zorkina, MD, Cand. Sci (Biolog.), Senior researcher, Mental-health clinic No. 1 named after N.A. Alexeev; V. Serbsky National Medical Research Centre of Psychiatry and Narcology of the Ministry of Health of the Russian Federation; e-Library SPIN-code: 3017-3328, Researcher ID: H-2424-2013, Scopus Author ID: 54584719100, ORCID: <https://orcid.org/0000-0003-0247-2717>

Alexandra Gennadievna Ochneva, Researcher, Scientific and Clinical Research Center of Neuropsychiatry, Mental-health clinic No. 1 named after N.A. Alexeev; Junior Researcher, V. Serbsky National Medical Research Centre of Psychiatry and Narcology of the Ministry of Health of the Russian Federation; e-Library SPIN-code: 3120-8975, ORCID: <https://orcid.org/0000-0003-4182-5503>

Angelina Ilyinichna Zeltzer, Laboratory researcher, Scientific and Clinical Research Center of Neuropsychiatry, Mental-health clinic No. 1

named after N.A. Alexeev; e-Library SPIN-code: 7430-0893, ORCID: <https://orcid.org/0009-0009-2715-1523>

Darya Anatolyevna Ryabinina, Junior researcher, Scientific and Clinical Research Center for Neuropsychiatry, Mental-health clinic No. 1 named after N.A. Alexeev; e-Library SPIN-code: 7000-7963, ORCID: <https://orcid.org/0009-0004-3756-5619>

Anna Mikhailovna Tsurina, Laboratory researcher, Scientific and Clinical Research Center of Neuropsychiatry, Mental-health clinic No. 1 named after N.A. Alexeev; student, Pirogov Russian National Research Medical University; ORCID: <https://orcid.org/0009-0008-0598-2564>

Elizaveta Alexandrovna Golubeva, Laboratory researcher, Scientific and Clinical Research Center of Neuropsychiatry, Mental-health clinic No. 1 named after N.A. Alexeev; student, I.M. Sechenov First Moscow State Medical University (Sechenov University); ORCID: <https://orcid.org/0009-0003-4024-5184>

Anna Sergeevna Goncharova, Project Manager, Moscow center for healthcare innovations; Scopus Author ID: 57194511103

Irina Vasilyevna Alekseenko, Cand. Sci (Biolog.), Deputy Director, Moscow center for healthcare innovations; Head of the Gene Immunotherapy Group, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry; Head of the Gene Oncology Sector, Kurchatov Institute; e-Library SPIN-code: 6827-4693, Scopus Author ID: 54408175400

George Petrovich Kostyuk, MD, Dr. Sci (Med.), Professor, Head of Mental-health clinic No. 1 named after N.A. Alexeev; e-Library SPIN-code: 3424-4544, Researcher ID: AAA-1682-2020, Scopus Author ID: 57200081884, ORCID: <https://orcid.org/0000-0002-3073-6305>

Anna Yurievna Morozova, MD, Cand. Sci (Med.), Senior researcher, Mental-health clinic No. 1 named after N.A. Alexeev; Head of the Laboratory of Experimental Neurobiology, V. Serbsky National Medical Research Centre of Psychiatry and Narcology of the Ministry of Health of the Russian Federation; e-Library SPIN-code: 3233-7638, Researcher ID: T-1361-2019, Scopus Author ID: 55648593900, ORCID: <https://orcid.org/0000-0002-8681-5299>

*corresponding author

References

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9
2. Javaid SF, Hashim IJ, Hashim MJ, et al. Epidemiology of anxiety disorders: global burden and sociodemographic associations. *Middle East Current Psychiatry*. 2023;30(1):44. doi: 10.1186/s43045-023-00315-3
3. Korabel'nikova EA. [Anxiety disorders in adolescents]. *Medicinskij sovet*. 2018;(18):34-43. In Russian. doi: 10.21518/2079-701X-2018-18-34-43
4. Evstifeeva SE, Shal'nova SA, Kucenko VA, et al. [Anxiety and depression: ten-year changes of prevalence and its association with demographic and socio-economic characteristics according to the ESSE-RF study]. *Kardiovaskuljarnaja terapija i profilaktika*. 2023;22(S8):68-79. In Russian. doi: 10.15829/1728-8800-2023-3796
5. Soljanik MA. [Depression in general medical practice: an educational and methodological guide]. Saint-Petersburg: Publishing house of the I. I. Mechnikov NWSMU; 2015. 41 p. In Russian.
6. Nair SS, Kwan SC, Ng CWM, et al. Approach to the patient with multiple somatic symptoms. *Singapore Med J*. 2021;62(5):252-258. doi: 10.11622/smedj.2021059

7. Barry MJ, Nicholson WK, Silverstein M, et al. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2023;329(23):2057–2067. doi: 10.1001/jama.2023.9297
8. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;52(2):69–77. doi: 10.1016/s0022-3999(01)00296-3
9. Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092
10. Annunziata MA, Muzzatti B, Bidoli E, et al. Hospital Anxiety and Depression Scale (HADS) accuracy in cancer patients. *Support Care Cancer*. 2020;28(8):3921–3926. doi: 10.1007/s00520-019-05244-8
11. Pogosova NV, Oganov RG, Bojcov SA, et al. [Psychosocial factors and life quality in coronary heart disease patients: results of the russian part of international multicenter study EUROASPIRE IV]. *Kardiovaskuljarnaja terapija i profilaktika*. 2017;16(5):20–26. In Russian. doi: 10.15829/1728-8800-2017-5-20-26
12. Klinkova AS, Kamenskaja OV, Loginova Iju, et al. [Features of psychoemotional status in patients with chronic thromboembolic pulmonary hypertension after cardiac surgery during the COVID-19 pandemic]. *Zhurnal nevrologii i psikiatrii im. S.S. Korsakova*. 2022;122(8):80–87. In Russian. doi: 10.17116/jnevro202212208180
13. Huang XJ, Ma HY, Wang XM, et al. Equating the PHQ-9 and GAD-7 to the HADS depression and anxiety subscales in patients with major depressive disorder. *J Affect Disord*. 2022;311:327–335. doi: 10.1016/j.jad.2022.05.079
14. Snijkers JTW, van den Oever W, Weerts ZZRM, et al. Examining the optimal cutoff values of HADS, PHQ-9 and GAD-7 as screening instruments for depression and anxiety in irritable bowel syndrome. *Neurogastroenterol Motil*. 2021;33(12):e14161. doi: 10.1111/nmo.14161
15. Zolotareva AA. [Adaptation of the Russian version of the Generalized Anxiety Disorder-7]. *Konsultativnaya psikhologiya i psikhoterapiya*. 2023;31(4):31–46. In Russian. doi: 10.17759/cpp.2023310402
16. Morozova MA, Potanin SS, Beniashvili AG, et al. [Validation of the Hospital Anxiety and Depression Scale Russian-language version in the general population]. *Profilakticheskaja medicina*. 2023;26(4):7–14. In Russian. doi: 10.17116/profmed2023260417
17. Muzzatti B, Agostinelli G, Bomben F, et al. Intensity and Prevalence of Psychological Distress in Cancer Inpatients: Cross-Sectional Study Using New Case-Finding Criteria for the Hospital Anxiety and Depression Scale. *Front Psychol*. 2022;13:875410. doi: 10.3389/fpsyg.2022.875410
18. Soares-Filho GL, Freire RC, Biancha K, et al. Use of the hospital anxiety and depression scale (HADS) in a cardiac emergency room: chest pain unit. *Clinics (Sao Paulo)*. 2009;64(3):209–214. doi: 10.1590/s1807-59322009000300011
19. Karpenko OA, Melihov OG, Tjazhel'nikov AA, et al. [Diagnosing and treating depression and anxiety in patients with cardiovascular disorders and diabetes mellitus in primary healthcare: is training of physicians enough for improvement? Consortium Psychiatricum]. 2021;2(4):2–12. In Russian. doi: 10.17816/CP112
20. Hu Z, Li M, Yao L, et al. The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: a network meta-analysis. *BMC gastroenterol*. 2021;21(1):23. doi: 10.1186/s12876-020-01593-5
21. Syunyakov T, Zorkina Y, Ochneva A, et al. Comparison of Anxiety and Depression Rates in Russian Health Care Professionals in 2020 and 2023. *Psychiatr Danub*. 2023;35(Suppl 2):296–301.
22. Morys JM, Bellwon J, Adamczyk K, et al. Depression and anxiety in patients with coronary artery disease, measured by means of self-report measures and clinician-rated instrument. *Kardiol Pol*. 2016;74(1):53–60. doi: 10.5603/KP.a2015.0116
23. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092
24. [The GTR-7 questionnaire (GAD7) and the WFSBP recommendations for the treatment of generalized anxiety disorder]. *Obozrenie psikiatrii i medicinskoj psihologii imeni V.M. Behtereva*. 2013;(2):71. In Russian.
25. Wu Y, Levis B, Sun Y, et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. *BMJ*. 2021;373:n972. doi: 10.1136/bmj.n972
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x
27. Kukshina AA, Kotel'nikova AV, Rassulova MA, et al. [Investigation of the psychometric properties of the hospital anxiety and depression scale (HADS) recommended for general medical practitioners, on a sample of patients with impaired motor functions]. *Klinicheskaja i special'naja psihologija*. 2023;12(2):1–24. In Russian. doi: 10.17759/cpse.2023120201
28. Karpenko OA, Syunyakov TS, Kulygina MA, et al. Impact of COVID-19 pandemic on anxiety, depression and distress—online survey results amid the pandemic in Russia. *Consort Psychiatr*. 2020;1(1):8–20. doi: 10.17650/2712-7672-2020-1-1-8-20
29. Andreescu C, Varon D. New research on anxiety disorders in the elderly and an update on evidence-based treatments. *Curr Psychiatry Rep*. 2015;17(7):53. doi: 10.1007/s11920-015-0595-8
30. Caldwell DM, Davies SR, Hetrick SE, et al. School-based interventions to prevent anxiety and depression in children and young people: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2019;6(12):1011–1020. doi: 10.1016/S2215-0366(19)30403-1
31. Lakasing E, Mirza Z. Anxiety and depression in young adults and adolescents. *Br J Gen Pract*. 2020;70(691):56–57. doi: 10.3399/bjgp20X707765
32. Sato H, Kawahara J. Selective bias in retrospective self-reports of negative mood states. *Anxiety Stress Coping*. 2011;24(4):359–367. doi: 10.1080/10615806.2010.543132
33. Howren MB, Suls J. The symptom perception hypothesis revised: depression and anxiety play different roles in concurrent and retrospective physical symptom reporting. *J Pers Soc Psychol*. 2011;100(1):182–195. doi: 10.1037/a0021715
34. Taple BJ, Griffith JW, Wolf MS. Interview Administration of PROMIS Depression and Anxiety Short Forms. *Health Lit Res Pract*. 2019;3(3):e196–e204. doi: 10.3928/24748307-20190626-01
35. Wang B, Nemesure MD, Park C, et al. Leveraging deep learning models to understand the daily experience of anxiety in teenagers over the course of a year. *J Affect Disord*. 2023;329:293–299. doi: 10.1016/j.jad.2023.02.084
36. Winsper C, Bilgin A, Thompson A, et al. The prevalence of personality disorders in the community: a global systematic review and meta-analysis. *Br J Psychiatry*. 2020;216(2):69–78. doi: 10.1192/bjp.2019.166
37. Lindhardt L, Nilsson LS, Munk-Jørgensen P, et al. Unrecognized schizophrenia spectrum and other mental disorders in youth disconnected from education and work-life. *Front Psychiatry*. 2022;13:1015616. doi: 10.3389/fpsyg.2022.1015616

38. Ruzhenkova VV, Ruzhenkov VA. [The problem of stigma in psychiatry and suicidology]. *Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Serija: Medicina. Farmacija.* 2012;(4):5–13. In Russian.
 39. Vertogradova OP, Stepanov IL, Maksimova NM, et al. [Clinical and pathogenetic aspects in typology of depression]. *Social'naja i klinicheskaja psihiatrija.* 2012;22(3):5–10. In Russian.
 40. Petrova NN, Palkin JuP, Faddeev DV, et al. [Comorbidity of depression and anxiety in clinical practice]. *Zhurnal nevrologii i psihiatrii im. C. C Korsakova.* 2021;121(4):31–37. In Russian. doi: 10.17116/jnevro202112104131
 41. Ionescu DF, Niciu MJ, Henter ID, et al. Defining anxious depression: a review of the literature. *CNS Spectr.* 2013;18(5):252–260. doi: 10.1017/S1092852913000114
 42. Reed GM, Sharan P, Rebello TJ, et al. The ICD–11 developmental field study of reliability of diagnoses of high-burden mental disorders: results among adult patients in mental health settings of 13 countries. *World Psychiatry.* 2018;17(2):174–186. doi: 10.1002/wps.20524
 43. Fatima SM, Khan S, Sadia R. The Relationship between Perceived Infectability and Psychological Well-being: The Mediating Role of Covid-19 Anxiety. *Psychol Russ.* 2023;16(2):63–71. doi: 10.11621/pir.2023.0205
 44. Klimochkina AY, Nekhorosheva EV, Kasatkina DA. Existential Well-being, Mental Health, and COVID-19: Reconsidering the Impact of Lockdown Stressors in Moscow. *Psychol Russ.* 2022;15(2):14–31. doi: 10.11621/pir.2022.0202
-